不同浓度马来酸噻吗洛尔滴眼液治疗浅表性婴幼儿血管瘤的临床研究

A Clinical Study of Different Concentrations of Timoiol Maleate Eye Drops for the Treatment of Superficial Infantile Hemangiomas

目的探讨不同浓度的马来酸噻吗洛尔滴眼液治疗浅表性婴幼儿血管瘤的疗效和安全性。方法2018年1月至2019年1月,87例年龄<6个月的浅表性婴幼儿血管瘤患儿随机分为2组,分别使用0.25%、0.5%两种不同浓度的马来酸噻吗洛尔滴眼液外敷于病灶表面,每日3次,每次20 min,随访6个月。采用Ⅳ级评分标准评估疗效,分析比较两组的临床疗效及安全性。结果0.25%浓度组41例,0.5%浓度组46例。治疗6个月后,0.25%浓度组有效率为63.4%、治愈率为14.6%;0.5%浓度组有效率为82.6%、治愈率为19.6%。后者有效率优于前者(P<0.05),两组治愈率无统计学差异(P>0.05)。所有患儿治疗期间均未见严重全身及局部不良反应。结论外用马来酸噻吗洛尔滴眼液治疗浅表性婴幼儿血管瘤简单、安全、有效,药物浓度可能是影响临床疗效的因素之一。

Objective To explore the efficacy and safety of timolol maleate eye drops with different concentrations for the treatment of superficial infantile hemangiomas.Methods From January 2018 to January 2019,patients aged within 6 months with superficial infantile hemangiomas were enrolled,and were randomly divided into 2 groups according to different concentration of timolol maleate eye drops:0.25%timolol group and 0.5%timolol group.Tiamolol maleate eye drops were applied externally by wet compressing for 20 minutes,three times a day for 6 months.The therapeutic effect was categorized into four grades,the therapeutic effect and safety of the two groups were compared.Results A total of 87 patients with superficial infantile hemangiomas were included in the study and were divided into 0.25%timolol group(n=41)and 0.5%timolol group(n=46).Six months after treatment,the effective rate and cure rate of 0.25%timolol group were 63.4%and 14.6%,the effective rate and cure rate of 0.5%timolol group were 82.6%and 19.6%.The effective rate of 0.5%timolol group was significantly higher than that of 0.25%timolol group(P<0.05).There was no significant difference of cure rate between the two groups(P>0.05).No severe systemic or local adverse reactions were observed during treatment.Conclusion Topical application of timolol maleate eye drops in the treatment of superficial infantile hemangiomas during proliferative phase is simple,effective and safe.Drug concentration may be one of the factors influencing clinical efficacy.